Clozapine dose-concentration relationships in plasma, hair and sweat specimens of schizophrenic patients

被引:32
作者
Cirimele, V
Kintz, P
Gosselin, O
Ludes, B
机构
[1] Inst Med Legale, F-67085 Strasbourg, France
[2] CHU Nancy, Serv Psychol Med, F-54201 Toul, France
关键词
clozapine; sweat; hair; analytical procedures; monitoring;
D O I
10.1016/S0379-0738(99)00172-3
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
The aim of the present study was to establish an analytical method for the determination of clozapine in sweat and to determine whether the clozapine level in hair and sweat were correlated to the daily dose of clozapine delivered to patients. Twenty-six subjects treated with clozapine at 200-700 mg/day for refractory psychosis were included in the study. Clozapine was determined in plasma by liquid chromatography coupled to a diode array detection system, after extraction with an organic solvent at pH 9.5. Clozapine was extracted from hair and sweat patches specimens by incubation in methanol overnight at 40 degrees C. The residues were analyzed by gas chromatography coupled to mass spectrometry in the electronic impact mode of detection. It was possible to determine clozapine in concentrations ranging from 30 to 1016 ng/ml in plasma (n=22), from 0.17 to 34.24 ng/mg in hair (n=23) and from 49 to 5609 ng/ patch in sweat (n=20). Preliminary results suggest a lack of correlation between daily regimen of clozapine and plasma levels of the drug. Therefore, a better dose-concentration relationship was observed in our study between daily dose and hair concentration (r=0.542, P<7%) or between daily dose and sweat concentration (r=0.589, P<6%), but with wide variations for patients at the same posology. However, the idea of using quantitative drug measurements in hair or sweat to ascertain whether a patient has taken his treatment exactly as prescribed will remain inapplicable. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:289 / 300
页数:12
相关论文
共 36 条
[1]  
ACKENHEIL M, 1989, PSYCHOPHARMACOLOGY, V99, P32
[2]  
BALDESSARINI RJ, 1991, NEW ENGL J MED, V324, P746
[3]   Clozapine and blood dyscrasias different from agranulocytosis [J].
Barbui, C ;
Campomori, A ;
Bonati, M .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1997, 42 (09) :981-982
[4]  
BAUMGARTNER WA, 1989, J FORENSIC SCI, V34, P1433
[5]   MONITORING DRUG-USE WITH A SWEAT PATCH - AN EXPERIMENT WITH COCAINE [J].
BURNS, M ;
BASELT, RC .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1995, 19 (01) :41-48
[6]  
CONE EJ, 1995, J ANAL TOXICOL, V19, P298
[7]   CLOZAPINE PLASMA-LEVELS DETERMINED BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ULTRAVIOLET DETECTION [J].
HARING, C ;
HUMPEL, C ;
AUER, B ;
SARIA, A ;
BARNAS, C ;
FLEISCHHACKER, W ;
HINTERHUBER, H .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1988, 428 (01) :160-166
[8]  
HASEGAWA M, 1993, J CLIN PSYCHOPHARM, V13, P383
[9]   SERUM CONCENTRATIONS OF CLOZAPINE DETERMINED BY NITROGEN SELECTIVE GAS-CHROMATOGRAPHY [J].
HEIPERTZ, R ;
PILZ, H ;
BECKERS, W .
ARCHIVES OF TOXICOLOGY, 1977, 37 (04) :313-318
[10]   RAPID AND SENSITIVE DETERMINATION OF CLOZAPINE IN HUMAN-PLASMA USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AND AMPEROMETRIC DETECTION [J].
HUMPEL, C ;
HARING, C ;
SARIA, A .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 491 (01) :235-239